
Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Novo Nordisk invests €2.1bn in production expansion
While Novo Nordisk’s main competitor Eli Lilly in the emerging market of effective drugs that fight obesity announced an investment of €11bn...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

Orakl Oncology SA raises €3m to advance tumour modelling
French precision oncology start-up Orakl Oncology has raised €3m in a seed financing round led by Speedinvest with additional investment from...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...